Bayer CropScience to use Cresset technology

By Kirsty Barnes

- Last updated on GMT

Bayer CropScience will use Cresset BioMolecular Discovery's
molecular field technology to identify novel early-stage active
compounds to develop into new agrochemicals for the crop science
industry.

This venture is the first major application of UK drug discovery technology company >Cresset's​ molecular field technology in the agrochemical arena.

Cresset's FieldScreen software is a virtual screening technology that allows users to search through in-house and commercially available compound libraries to select compounds with diverse structures but the same biological function.

What used to be a laborious process for companies in early stage-drug development can now be accomplished in a fraction of the time with Cresset's FieldScreen - the first validated field analysis software for drug candidate selection.

FieldScreen's hit selection is uniquely accomplished by an analysis of the molecular field around the compound and not the molecular structure itself, allowing it to find completely novel hits from screening just a few hundred compounds rather than hundreds of thousands.

"Cresset's FieldScreen technique is complementary to our existing software tools in computational chemistry and we feel confident that this approach provides another step towards further improving our early phase research activities," said Michael Schindler, senior scientist at >Bayer CropScience.

Bayer CropScience, a subsidiary of Bayer with annual sales of € 6 bn, is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology - an area which it is actively developing.

In December the company acquired Germany's Icon Genetics, involved in the development and use of engineered plants to create pharmaceuticals, in a move to strengthen its activities in producing specific plant-made pharmaceuticals.

Related topics Ingredients Processing equipment

Related news

Show more

Related products

Solution for challenging antibodies – Planova™ S20N

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd. | 24-Sep-2024 | White Paper

Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars